DTIL

insider transactions

PRECISION BIOSCIENCES INC — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-107.6K

0 buy · 107.6K sell

Net value · 365d

-$431.3K

$0 in · $431.3K out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 107.6K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 3, 26

Shari Lisa Pire

Director

$0

21.0K sh

Own New
Grant·A
Jun 3, 26

Geno J Germano

Director

$0

21.0K sh

Own New
Grant·A
Jun 3, 26

Stanley Frankel

Director

$0

21.0K sh

Own New
Grant·A
Jun 3, 26

Kevin Buehler

Director

$0

21.0K sh

Own New
Grant·A
Jun 3, 26

Melinda Brown

Director

$0

21.0K sh

Own New
Grant·A
Jun 1, 26

Jefferson J. Smith

Chief Research Officer

$0

57.4K sh

Own New
Grant·A
Jun 1, 26

Dario Scimeca

General Counsel and Secretary

$0

107.6K sh

Own New
Grant·A
Jun 1, 26

John Alexander Kelly KEY

Chief Financial Officer

$0

193.7K sh

Own New
Grant·A
Jun 1, 26

Michael Amoroso KEY

President and CEO

$0

573.9K sh

Own New
Exercise·M
May 20, 26

Shari Lisa Pire

Director

$0

21.0K sh

Own New
Exercise·M
May 20, 26

Shari Lisa Pire

Director

—

21.0K sh

Own +150%
Exercise·M
May 20, 26

Geno J Germano

Director

$0

21.0K sh

Own New
Exercise·M
May 20, 26

Geno J Germano

Director

—

21.0K sh

Own +88%
Exercise·M
May 20, 26

Stanley Frankel

Director

$0

21.0K sh

Own New
Exercise·M
May 20, 26

Stanley Frankel

Director

—

21.0K sh

Own +108%
Exercise·M
May 20, 26

Kevin Buehler

Director

$0

21.0K sh

Own New
Exercise·M
May 20, 26

Kevin Buehler

Director

—

21.0K sh

Own +75%
Exercise·M
May 20, 26

Melinda Brown

Director

$0

21.0K sh

Own New
Exercise·M
May 20, 26

Melinda Brown

Director

—

21.0K sh

Own +90%
Grant·A
May 14, 26

Geno J Germano

Director

$0

21.2K sh

Own New
Sell·S
Feb 18, 26

Dario Scimeca

General Counsel and Secretary · 10b5-1

$18.9K

4.9K sh · $3.84

Own -8%
Sell·S
Feb 18, 26

Jefferson J. Smith

Chief Research Officer · 10b5-1

$18.9K

4.9K sh · $3.84

Own -4%
Sell·S
Feb 18, 26

John Alexander Kelly KEY

Chief Financial Officer · 10b5-1

$31.3K

8.1K sh · $3.84

Own -6%
Sell·S
Feb 18, 26

Michael Amoroso KEY

President and CEO · 10b5-1

$78.9K

20.6K sh · $3.84

Own -8%
Exercise·M
Feb 17, 26

Dario Scimeca

General Counsel and Secretary · 10b5-1

$0

16.7K sh

Own +100%
Exercise·M
Feb 17, 26

Dario Scimeca

General Counsel and Secretary · 10b5-1

$0

16.7K sh

Own +37%
Exercise·M
Feb 17, 26

Jefferson J. Smith

Chief Research Officer · 10b5-1

$0

16.7K sh

Own +100%
Exercise·M
Feb 17, 26

Jefferson J. Smith

Chief Research Officer · 10b5-1

$0

16.7K sh

Own +15%
Exercise·M
Feb 17, 26

John Alexander Kelly KEY

Chief Financial Officer · 10b5-1

$0

27.6K sh

Own +100%
Exercise·M
Feb 17, 26

John Alexander Kelly KEY

Chief Financial Officer · 10b5-1

$0

27.6K sh

Own +26%
Exercise·M
Feb 17, 26

Michael Amoroso KEY

President and CEO · 10b5-1

$0

67.8K sh

Own +100%
Exercise·M
Feb 17, 26

Michael Amoroso KEY

President and CEO · 10b5-1

$0

67.8K sh

Own +35%
Sell·S
Jan 22, 26

Michael Amoroso KEY

President and CEO · 10b5-1

$145.1K

34.8K sh · $4.17

Own -15%
Sell·S
Jan 21, 26

Dario Scimeca

General Counsel and Secretary · 10b5-1

$35.7K

8.9K sh · $4.03

Own -17%
Sell·S
Jan 21, 26

Jefferson J. Smith

Chief Research Officer · 10b5-1

$41.1K

10.2K sh · $4.03

Own -8%
Exercise·M
Jan 21, 26

Jefferson J. Smith

Chief Research Officer · 10b5-1

—

16.2K sh

Own +16%
Sell·S
Jan 21, 26

John Alexander Kelly KEY

Chief Financial Officer · 10b5-1

$61.3K

15.2K sh · $4.03

Own -13%
Exercise·M
Jan 20, 26

Dario Scimeca

General Counsel and Secretary · 10b5-1

$0

14.9K sh

Own New
Exercise·M
Jan 20, 26

Dario Scimeca

General Counsel and Secretary · 10b5-1

$0

8.4K sh

Own New
Exercise·M
Jan 20, 26

Dario Scimeca

General Counsel and Secretary · 10b5-1

$0

2.0K sh

Own New
Exercise·M
Jan 20, 26

Dario Scimeca

General Counsel and Secretary · 10b5-1

$0

14.9K sh

Own +39%
Exercise·M
Jan 20, 26

Dario Scimeca

General Counsel and Secretary · 10b5-1

$0

8.4K sh

Own +28%
Exercise·M
Jan 20, 26

Dario Scimeca

General Counsel and Secretary · 10b5-1

$0

2.0K sh

Own +7%
Exercise·M
Jan 20, 26

Jefferson J. Smith

Chief Research Officer · 10b5-1

$0

16.2K sh

Own New
Exercise·M
Jan 20, 26

Jefferson J. Smith

Chief Research Officer · 10b5-1

$0

10.4K sh

Own New
Exercise·M
Jan 20, 26

Jefferson J. Smith

Chief Research Officer · 10b5-1

$0

2.5K sh

Own New
Exercise·M
Jan 20, 26

Jefferson J. Smith

Chief Research Officer · 10b5-1

—

10.4K sh

Own +11%
Exercise·M
Jan 20, 26

Jefferson J. Smith

Chief Research Officer · 10b5-1

—

2.5K sh

Own +3%
Exercise·M
Jan 20, 26

John Alexander Kelly KEY

Chief Financial Officer · 10b5-1

$0

26.6K sh

Own New
Exercise·M
Jan 20, 26

John Alexander Kelly KEY

Chief Financial Officer · 10b5-1

$0

13.9K sh

Own +1390000%
Exercise·M
Jan 20, 26

John Alexander Kelly KEY

Chief Financial Officer · 10b5-1

$0

3.9K sh

Own New
Exercise·M
Jan 20, 26

John Alexander Kelly KEY

Chief Financial Officer · 10b5-1

—

26.6K sh

Own +28%
Exercise·M
Jan 20, 26

John Alexander Kelly KEY

Chief Financial Officer · 10b5-1

—

13.9K sh

Own +17%
Exercise·M
Jan 20, 26

John Alexander Kelly KEY

Chief Financial Officer · 10b5-1

—

3.9K sh

Own +5%
Exercise·M
Jan 20, 26

Michael Amoroso KEY

President and CEO · 10b5-1

$0

69.4K sh

Own New
Exercise·M
Jan 20, 26

Michael Amoroso KEY

President and CEO · 10b5-1

$0

37.1K sh

Own New
Exercise·M
Jan 20, 26

Michael Amoroso KEY

President and CEO · 10b5-1

$0

8.9K sh

Own New
Exercise·M
Jan 20, 26

Michael Amoroso KEY

President and CEO · 10b5-1

—

69.4K sh

Own +43%
Exercise·M
Jan 20, 26

Michael Amoroso KEY

President and CEO · 10b5-1

—

37.1K sh

Own +30%
Exercise·M
Jan 20, 26

Michael Amoroso KEY

President and CEO · 10b5-1

—

8.9K sh

Own +8%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 3, 2026	Shari Lisa Pire	Director	Grant A	21.0K	New	—	$0
Jun 3, 2026	Geno J Germano	Director	Grant A	21.0K	New	—	$0
Jun 3, 2026	Stanley Frankel	Director	Grant A	21.0K	New	—	$0
Jun 3, 2026	Kevin Buehler	Director	Grant A	21.0K	New	—	$0
Jun 3, 2026	Melinda Brown	Director	Grant A	21.0K	New	—	$0
Jun 1, 2026	Jefferson J. Smith	Chief Research Officer	Grant A	57.4K	New	—	$0
Jun 1, 2026	Dario Scimeca	General Counsel and Secretary	Grant A	107.6K	New	—	$0
Jun 1, 2026	John Alexander Kelly KEY	Chief Financial Officer	Grant A	193.7K	New	—	$0
Jun 1, 2026	Michael Amoroso KEY	President and CEO	Grant A	573.9K	New	—	$0
May 20, 2026	Shari Lisa Pire	Director	Exercise M	21.0K	New	—	$0
May 20, 2026	Shari Lisa Pire	Director	Exercise M	21.0K	+150%	—	—
May 20, 2026	Geno J Germano	Director	Exercise M	21.0K	New	—	$0
May 20, 2026	Geno J Germano	Director	Exercise M	21.0K	+88%	—	—
May 20, 2026	Stanley Frankel	Director	Exercise M	21.0K	New	—	$0
May 20, 2026	Stanley Frankel	Director	Exercise M	21.0K	+108%	—	—
May 20, 2026	Kevin Buehler	Director	Exercise M	21.0K	New	—	$0
May 20, 2026	Kevin Buehler	Director	Exercise M	21.0K	+75%	—	—
May 20, 2026	Melinda Brown	Director	Exercise M	21.0K	New	—	$0
May 20, 2026	Melinda Brown	Director	Exercise M	21.0K	+90%	—	—
May 14, 2026	Geno J Germano	Director	Grant A	21.2K	New	—	$0
Feb 18, 2026	Dario Scimeca 10b5-1	General Counsel and Secretary	Sell S	4.9K	-8%	$3.84	$18.9K
Feb 18, 2026	Jefferson J. Smith 10b5-1	Chief Research Officer	Sell S	4.9K	-4%	$3.84	$18.9K
Feb 18, 2026	John Alexander Kelly KEY 10b5-1	Chief Financial Officer	Sell S	8.1K	-6%	$3.84	$31.3K
Feb 18, 2026	Michael Amoroso KEY 10b5-1	President and CEO	Sell S	20.6K	-8%	$3.84	$78.9K
Feb 17, 2026	Dario Scimeca 10b5-1	General Counsel and Secretary	Exercise M	16.7K	+100%	—	$0
Feb 17, 2026	Dario Scimeca 10b5-1	General Counsel and Secretary	Exercise M	16.7K	+37%	—	$0
Feb 17, 2026	Jefferson J. Smith 10b5-1	Chief Research Officer	Exercise M	16.7K	+100%	—	$0
Feb 17, 2026	Jefferson J. Smith 10b5-1	Chief Research Officer	Exercise M	16.7K	+15%	—	$0
Feb 17, 2026	John Alexander Kelly KEY 10b5-1	Chief Financial Officer	Exercise M	27.6K	+100%	—	$0
Feb 17, 2026	John Alexander Kelly KEY 10b5-1	Chief Financial Officer	Exercise M	27.6K	+26%	—	$0
Feb 17, 2026	Michael Amoroso KEY 10b5-1	President and CEO	Exercise M	67.8K	+100%	—	$0
Feb 17, 2026	Michael Amoroso KEY 10b5-1	President and CEO	Exercise M	67.8K	+35%	—	$0
Jan 22, 2026	Michael Amoroso KEY 10b5-1	President and CEO	Sell S	34.8K	-15%	$4.17	$145.1K
Jan 21, 2026	Dario Scimeca 10b5-1	General Counsel and Secretary	Sell S	8.9K	-17%	$4.03	$35.7K
Jan 21, 2026	Jefferson J. Smith 10b5-1	Chief Research Officer	Sell S	10.2K	-8%	$4.03	$41.1K
Jan 21, 2026	Jefferson J. Smith 10b5-1	Chief Research Officer	Exercise M	16.2K	+16%	—	—
Jan 21, 2026	John Alexander Kelly KEY 10b5-1	Chief Financial Officer	Sell S	15.2K	-13%	$4.03	$61.3K
Jan 20, 2026	Dario Scimeca 10b5-1	General Counsel and Secretary	Exercise M	14.9K	New	—	$0
Jan 20, 2026	Dario Scimeca 10b5-1	General Counsel and Secretary	Exercise M	8.4K	New	—	$0
Jan 20, 2026	Dario Scimeca 10b5-1	General Counsel and Secretary	Exercise M	2.0K	New	—	$0
Jan 20, 2026	Dario Scimeca 10b5-1	General Counsel and Secretary	Exercise M	14.9K	+39%	—	$0
Jan 20, 2026	Dario Scimeca 10b5-1	General Counsel and Secretary	Exercise M	8.4K	+28%	—	$0
Jan 20, 2026	Dario Scimeca 10b5-1	General Counsel and Secretary	Exercise M	2.0K	+7%	—	$0
Jan 20, 2026	Jefferson J. Smith 10b5-1	Chief Research Officer	Exercise M	16.2K	New	—	$0
Jan 20, 2026	Jefferson J. Smith 10b5-1	Chief Research Officer	Exercise M	10.4K	New	—	$0
Jan 20, 2026	Jefferson J. Smith 10b5-1	Chief Research Officer	Exercise M	2.5K	New	—	$0
Jan 20, 2026	Jefferson J. Smith 10b5-1	Chief Research Officer	Exercise M	10.4K	+11%	—	—
Jan 20, 2026	Jefferson J. Smith 10b5-1	Chief Research Officer	Exercise M	2.5K	+3%	—	—
Jan 20, 2026	John Alexander Kelly KEY 10b5-1	Chief Financial Officer	Exercise M	26.6K	New	—	$0
Jan 20, 2026	John Alexander Kelly KEY 10b5-1	Chief Financial Officer	Exercise M	13.9K	+1390000%	—	$0
Jan 20, 2026	John Alexander Kelly KEY 10b5-1	Chief Financial Officer	Exercise M	3.9K	New	—	$0
Jan 20, 2026	John Alexander Kelly KEY 10b5-1	Chief Financial Officer	Exercise M	26.6K	+28%	—	—
Jan 20, 2026	John Alexander Kelly KEY 10b5-1	Chief Financial Officer	Exercise M	13.9K	+17%	—	—
Jan 20, 2026	John Alexander Kelly KEY 10b5-1	Chief Financial Officer	Exercise M	3.9K	+5%	—	—
Jan 20, 2026	Michael Amoroso KEY 10b5-1	President and CEO	Exercise M	69.4K	New	—	$0
Jan 20, 2026	Michael Amoroso KEY 10b5-1	President and CEO	Exercise M	37.1K	New	—	$0
Jan 20, 2026	Michael Amoroso KEY 10b5-1	President and CEO	Exercise M	8.9K	New	—	$0
Jan 20, 2026	Michael Amoroso KEY 10b5-1	President and CEO	Exercise M	69.4K	+43%	—	—
Jan 20, 2026	Michael Amoroso KEY 10b5-1	President and CEO	Exercise M	37.1K	+30%	—	—
Jan 20, 2026	Michael Amoroso KEY 10b5-1	President and CEO	Exercise M	8.9K	+8%	—	—

About DTIL insider trading

This page tracks insider transactions for PRECISION BIOSCIENCES INC (DTIL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.